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LysineN-Methylation of lysine and arginine residues has emerged as amajormechanism of transcriptional regulation in
eukaryotes. In humans, Nε-methyllysine residue demethylation is catalysed by two distinct subfamilies of
demethylases (KDMs), the ﬂavin-dependent KDM1 subfamily and the 2-oxoglutarate- (2OG) dependent JmjC
subfamily, which both employ oxidative mechanisms. Modulation of histone methylation status is proposed to
be important in epigenetic regulation and has substantial medicinal potential for the treatment of diseases in-
cluding cancer and genetic disorders. This article provides an introduction to the enzymology of the KDMs and
the therapeutic possibilities and challenges associated with targeting them, followed by a review of reported
KDM inhibitors and their mechanisms of action from kinetic and structural perspectives. This article is part of a
Special Issue entitled: Methylation: A Multifaceted Modiﬁcation — looking at transcription and beyond.
© 2014 Elsevier B. V. Open access under CC BY license.1. Introduction
Post-oligomerisation modiﬁcations to the nucleic acid and protein
components of chromatin are of central importance in eukaryotic tran-
scriptional regulation. Established modiﬁcations to chromatin include
methylation of DNA and histones, and further modiﬁcations to histones
include acetylation, phosphorylation, and ubiquitination, with the
N-terminal tail of histone H3 being subjected to a particularly complex
set of modiﬁcations. These modiﬁcations, together with other factors,
are proposed to substantially contribute to the regulation of gene expres-
sion in a context-dependent manner, in part by affecting the accessibility
of DNAsequences for transcription [1–3]. Thepost-translationalmodiﬁca-
tions affect chromatin structure and dynamics, the lifetimes of chromatin
components, andmediate chromatin binding interactions. Aberrantmod-
iﬁcation patterns to chromatin have been associated with the onset and
progression of both germline and somatic diseases, ranging from mental
disorders to many cancers [4–6]. Presently, it seems quite possible that
most, if not all, major human diseases (including at least some infectious
diseases) will be linked to changes in post-oligomerisation modiﬁcations
to chromatin. Consequently, many of the enzymes that catalyse thesen:AMultifacetedModiﬁcation—
k (C.J. Schoﬁeld),
Y license.modiﬁcations and their removal (sometimes referred to as ‘writers’ and
‘erasers’, respectively), aswell as themultiple binding domains that inter-
act with them, are being pursued as small-molecule targets for therapeu-
tic beneﬁt. Small molecules targeting chromatin-modifying enzymes for
cancer treatment are already in clinical use (e.g. DNA methyltransferase
inhibitors (Azacitidine, Decitabine) and histone deacetylase inhibitors
(Vorinostat, Romidepsin)), and others are in trials [7–9].
N-Methylations of both DNA and histones are chromatin modiﬁca-
tions of central importance in (epi)genetics. Due to the strength of the
C–N bond, N-methylation was once thought to be irreversible, at
least via direct enzymatic catalysis; however, it is now clear that
N-methylation of DNA (and RNA) is both common and can be directly
reversed by the action of demethylases (note that indirect methods of
repair of methylated DNA, for example base excision repair, are well-
established, but beyond the scope of this article).
The available evidence is that protein N-methylation occurs princi-
pally, but not exclusively, on the histone lysyl and arginyl side chains
of histones H3 and H4. There is also evidence, both from ‘global’ prote-
omic as well as focused studies, that many other proteins are
N-methylated (and likely demethylated), including some associated
with transcriptional regulation (e.g. methylation of p53 [10] and
NF-κB [11,12]). In contrast to histone lysine acetylation, which results
in transcriptional activation, histone methylation can either enable
context-dependent activation or repression of transcription. In general,
methylation of histone H3 at Lys9 or Lys27 (H3K9 or H3K27) or histone
H4 at Lys20 (H4K20) correlates with transcriptional repression, where-
as methylation of H3K4, H3K36 and H3K79 correlates with enhanced
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extent, the presence of other chromatin modiﬁcations, and many
other regulatory factors.
The available evidence is that lysine is one of, if not the, most
diversely and extensivelymodiﬁed componentmonomer of any biolog-
ical polymer [14,15]. Lysine residues can be altered by modiﬁcations
including acetylation, crotonylation, ubiquitination (multiple forms),
hydroxylation (at least several types), and by Nε-methylation. Lysine
and arginine residues can each exist in four biologically identiﬁedmeth-
ylation states (unmodiﬁed, mono-, di- and tri-Nε-methylation for lysine
and unmodiﬁed, mono-, di-(symmetric)- and di-(asymmetric)-
methylation for arginine) (Fig. 1A). The possibility of combinations of
modiﬁcations both on the same residue and on other histone residues
enables an enormity of potential complexity that is proposed to be a
central factor in the regulation of gene expression. Deﬁning how the
combinations of post-oligomerisation modiﬁcations to chromatin, and
associated other variables (e.g. association of binding partner proteins)
regulate context-dependent transcription of individual open reading
frames is a major current biological challenge. Substantial difﬁculties
arise in epigenetic regulation, including with inhibition, due to the
context-dependent nature of effects, linked, at least in higher organ-
isms, to redundancy and adaptation. The precise mechanisms of howH3K4me2
FAD
Kme0 Kme1 Kme2 Kme3 Rme0
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Fig. 1.Histone lysyl demethylation is catalysed by histone demethylases (KDMs). (A) Methylat
trimethylated on their Nε-amino groups (Kme1, Kme2 and Kme3 respectively), whereas argini
and Rme2 respectively). Dimethylated arginine exists in either symmetric (Rme2s) or asymm
deaminated to form citrulline (Rcit), as catalysed by peptidylarginine deiminase activity. (B) M
The KDM1 subfamily only accepts mono- and dimethylated lysines as substrates.N-methylation and other modiﬁcations regulate the transcription of in-
dividual open reading frames are complex and may take a long time,
possibly decades, to be unravelled in detailed chemical terms. Whilst
such an understanding is desirable, one would hope that it is not essen-
tial for therapeutic beneﬁt to occur based on existing, or soon to be ac-
quired, knowledge. Many enzymes catalysing chromatin modiﬁcations
and their reversal, e.g. methylation/demethylation, have been identi-
ﬁed; along with non-catalytic binding proteins, some are being pursued
as therapeutic targets. Currently, the main therapeutic focus regarding
methyltransferases and demethylases is cancer, but in the longer term
the complexity of transcriptional regulation, and in particular methyla-
tion, suggests that the possibilities for selective treatment of many
diseases involving transcriptional regulation are very substantial.
Histone methylation is catalysed by S-adenosylmethionine- (SAM)
dependent histone lysine methyltransferases (KMTs) and protein
arginine methyltransferases (PRMTs). Over-expression as well as both
activating and inactivatingmutations ofmany KMTs correlate with can-
cer [16]. In several acute leukaemias, the mixed lineage leukaemia
(MLL) gene undergoes chromosomal translocation resulting in an
oncogenic MLL fusion protein, which recruits DOT1L, an H3K79 KMT,
causing aberrant methylation and transcription of leukaemeogenic
genes [17,18]. EZH2, a human H3K27 KMT which is a catalyticH3K9me3
E190
H188
H276
NOG
Y132
K206
Rme1 Rme2s Rme2a Rcit
ion states of lysine and arginine residues in histones. Lysine residues may bemono-, di- or
ne residues may be either mono- or dimethylated on their Nω-guanidino nitrogens (Rme1
etric (Rme2a) forms, depending upon the positions of methylation. Arginine may also be
echanisms of lysyl demethylation catalysed by the KDM1 and JmjC (KDM2-7) subfamilies.
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cancers and is associated with poor prognosis in breast and prostate
cancers [19–21]. Other KMTs, such as the Nuclear Binding SET Domain
protein (NSD1), SUV39H1 and SUV39H2, are also linked to cancers
(see Ref. [16] for review). A DOT1L KMT inhibitor is in clinical develop-
ment forMLL-rearranged leukaemia [22]. A KMT EZH2 inhibitor [23] is
being targeted at non-Hodgkin lymphoma [24]. Together, with the clin-
ical use of DNAmethyltransferase inhibitors [25], these studies validate
the modulation of chromatin methylation status for cancer therapy.
Over 20 human histone Nε-methylated lysine residue demethylases
(KDMs) have been identiﬁed, with many exhibiting dysregulated
expression patterns in disease [26,27]. As with the KMTs, emerging
evidence suggests that some KDMs are required for tumour growth.
Consequently, KDMs have emerged as interesting new targets for ther-
apeutic intervention. Demethylation of mono-N-methylated arginine
residues on histones is proposed to be catalysed by the peptidyl arginine
deiminases (PADIs) which catalyse hydrolysis to give citrulline andme-
thylamine [28,29]. Although there are reports of a ‘direct’ N-methylated
arginine residue demethylase [30,31], i.e. JMJD6, these are controversial.
Subsequent work has revealed that JMJD6 is a lysine C-5 hydroxylase
acting on arginine-rich regions of splicing regulatory proteins [32,33].
Thus, at present there is no deﬁnitive evidence for direct reversal of ar-
ginine N-methylation.
KDMs are classiﬁed into two subfamilies depending on their se-
quence homologies and catalyticmechanisms.Members of theﬁrst iden-
tiﬁed subfamily, the KDM1 subfamily (or lysine-speciﬁc demethylases,
LSDs), are related to the well-characterised monoamine oxidases
(MAOs) and utilise the cosubstrate ﬂavin adenine dinucleotide (FAD)
during catalysis of demethylation; methyl group oxidation is proposed
to proceed via hydride transfer from the Nε-methyl group onto FAD,
forming an imine which is unstable to hydrolysis (Fig. 1B) [26]. For
chemical reasons this mechanism cannot apply to quaternary amines,
hence the KDM1 subfamily likely does not act on N-trimethylated lysine
residues. KDM1A, the most studied KDM1 enzyme, catalyses removal of
methyl groups from mono- and dimethylated lysine residues at H3K4
and, potentially, H3K9, while KDM1B catalyses demethylation speciﬁcal-
ly at H3K4 [26]. KDM1A is reported to be oncogenic and/or over-
expressed in cancers including leukaemias and solid tumours [34–37].
Notably, KDM1A is speciﬁc for H3K4me1/me2 when a component of
the CoREST corepressor complex [38], but in vivo work has suggested
that the presence of the androgen receptor (AR)may change its speciﬁc-
ity fromH3K4 to H3K9 [39]. Thus, KDM1Amight potentially act either as
a transcriptional corepressor or coactivator depending on its binding
partners and substrates. This example nicely illustrates the importance
of why a detailed biological understanding of context-dependent roles
will be useful in interpreting the pharmacological effects of KDM
inhibitors.
The JmjC domain-containing KDMs (KDM2-7 subfamilies; JmjC
KDMs) represent the larger KDM class, comprising about 20 human en-
zymes which are grouped into ﬁve subfamilies (KDM2/7, KDM3, KDM4,
KDM5, and KDM6) [40]. They can catalyse the demethylation of mono-,
di- and trimethylated lysines at multiple sites, using 2OG and dioxygen
as cosubstrates and Fe(II) as a cofactor [26]. The JmjC KDMs are over-
expressed in multiple types of cancer cells [34,37]. Some JmjC KDMs
are implicated in neural development and/or function and are associated
with conditions including X-linked mental retardation, autism and mid-
line defects [41–44]. The JmjC KDMs are related to N-methyl DNA and
RNA demethylases (AlkB homologues and the fat mass and obesity-
related protein, FTO) and other nucleic acid oxygenases includingFig. 2.Mechanism-based inhibitors of the KDM1 subfamily. (A) Structures of representativeme
pargyline 3were among the ﬁrst reported inhibitors of KDM1,which led to the development of
and peptidic inhibitor (14) cross-linked to FAD in the active site of KDM1A (PDB IDs: 2Z3Y [63
crystal structures of tranylcypromine analogues (FAD adducts) in the active site of KDM1A (PD
binding pocket. (D) Proposed structures of adducts formed by reaction of tranylcypromine wit
tallographic analyses (see section E). (E) Structures of FAD adducts of mechanism-based inhib
2XAJ [61], 2XAG [61], 2XAH [61], 2XAS [61], 2XAQ [61], 2Z5U [63], 3ABT [66], 3ABU, 4GUU [15the TET (ten eleven translocation) hydroxylases which catalyse oxida-
tion of the methyl group of 5-methylcytosine bases to give C-5
hydroxymethyl-, formyl, and carboxycytosine [45]. There is evidence
that JmjC KDM-catalysed demethylation proceeds via the consensus
mechanism for 2OG oxygenase catalysis: following sequential active
site binding of 2OG, substrate, then dioxygen, oxidative decarboxylation
occurs to give succinate, carbon dioxide and an Fe(IV)-oxo intermediate,
which reacts with the Nε-methyl group, either via a radical rebound or
direct insertion process to form an unstable hemiaminal [26]. Subse-
quent fragmentation produces the demethylated lysine and formalde-
hyde (Fig. 1B) [46,47]. Thus, the overall reactions of the two KDM
subfamilies are closely related; however, the JmjC KDMs are capable of
catalysing demethylation of trimethylated lysines because their mecha-
nism does not require imine formation.
The catalytic domain of the KDM1 subfamily, the amine oxidase-like
(AOL) domain, is related to the large superfamily of monoamine oxi-
dases [48], with MAO-A and MAO-B being the closest homologues
[49]. MAOs catalyse the oxidation of monoamine neurotransmitters,
such as serotonin and dopamine. Similarly, the catalytic domains of
JmjC KDMs, the JmjC domains, are also part of the large superfamily of
2OG-dependent oxygenases, whichhas approximately 60humanmem-
bers [50]. In addition to the roles of the JmjC KDMs in epigenetic regula-
tion, other 2OG oxygenases play key roles in human biology, including
in fatty acid metabolism, collagen biosynthesis, protein biosynthesis,
nucleic acid repair/modiﬁcation and hypoxic response [50].
Pioneering inhibitor development strategies for both KDM subfam-
ilies initially focused on the testing of genericmechanism-related inhib-
itors for each family of enzymes. For example, theﬁrst generation KDM1
inhibitor, tranylcypromine (2, Fig. 2), is an FDA-approvedMAO inhibitor
that is used to treat mood and anxiety disorders [51]. Broad-spectrum
2OG oxygenase inhibitors, such as the 2OG mimetics N-oxalylglycine
(NOG, 32, Fig. 4) and pyridine-2,4-dicarboxylate (2,4-PDCA, 47, Fig. 4),
are also JmjC KDM inhibitors [52,53]. Given the structural similarity of
KDMs and the conservation of active site features with multiple homol-
ogous enzymes, one of the major challenges for future KDM inhibitor
discovery is to develop inhibitors selective for particular (sets of)
KDMs. Although beyond the scope of this review, it is also important
to note that the activities of most, if not all KDMs, are likely directed
by binding domains contiguous with the ‘catalytic’ JmjC domains
(e.g. the KDM4 enzymes contain Tudor and PHD domains in addition
to the JmjC domain) or by non-covalent interactionswith targeting pro-
teins (see above for KDM1A); these non-catalytic domains are also of
therapeutic interest in isolation and in combination with KDM inhibi-
tors. KDM inhibitors are required for target validation and for probing
biological function. Below, we describe recent advances in the develop-
ment of inhibitors for the KDM1 and JmjC KDM subfamilies, and discuss
future strategies for KDM inhibitor discovery.
2. KDM1 inhibitors
2.1. Tranylcypromine and analogues
The known amine oxidase inhibitors phenelzine (1, Fig. 2A) [54],
tranylcypromine (PCPA) (2, Fig. 2A) [54,55], and pargyline (3, Fig. 2A)
[39] were amongst the ﬁrst compounds reported to inhibit KDM1 catal-
ysis. Although subsequent studies with pargyline did not reveal KDM1
inhibition [54,56], both the hydrazine derivative phenelzine 1 and cy-
clopropane derivative tranylcypromine 2 were subsequently found to
inhibit KDM1A both in vitro and in cell-based experiments, withchanism-based KDM1 inhibitors. TheMAO inhibitors phenelzine 1, tranylcypromine 2 and
KDM1-selective analogues. (B) Views fromX-ray crystal structures of tranylcypromine (2)
] and 2UXN [155] respectively). Views from both structures are overlaid. (C) Views from
B IDs: 2XAJ, 2XAG, 2XAH, 2XAS and 2XAQ) [61]. The analogues protrude into the substrate
h FAD in the active site of KDM1s. There is evidence for three of the structures from crys-
itors bound in the active sites of KDM1s (views of structures are from PDB IDs: 2Z3Y [63],
6] and 2UXN [155]).
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Fig. 3. Structures of representative non-tranylcypromine-based KDM1 subfamily inhibitors. Bisguanidines, bisbiguanides, polyamines and (thio)urea-containing compounds (for exam-
ples see 21–24) have all been shown to inhibit KDM1 activity in vitro, with some showing effects in cells. A detailed mechanistic/structural understanding of KDM1 inhibition by these
compounds is presently not available. Recently, a series of other inhibitors of the KDM1 subfamily have been identiﬁed, including Namolin (26), aminothiazoles (27–29), benzohydrazides
(30) and a tricyclic pyridine (31).
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against amine oxidases [54,57]. Structural and mechanistic studies
with MAOs have shown that phenelzine 1 and tranylcypromine 2
react with the co-substrate FAD via their hydrazine and cyclopropyl
groups respectively, forming covalent adducts within the active site
[58–60]. Analogous ‘suicide’ inactivation has also been reported for
KDM1A inhibition by tranylcypromine 2 (Fig. 2) [55,61–63].
Subsequent studies, whichwere partly informed by crystallographic
analyses, have utilised tranylcypromine 2 as a scaffold for the develop-
ment ofmore selective cyclopropane-based KDM1 inhibitors (for repre-
sentative structures of analogues, see Fig. 2A) [61,64–71]. To date, a
number of tranylcypromine analogues, modiﬁed on both the aromatic
ring and amino groups, have been tested for KDM1 activity, resulting
in the generation of inhibitors which display both improved inhibitory
potency against KDM1A and, in some cases, improved selectivity.
Improvements in bothpotency and selectivitywere observed for com-
pounds substituted on the aromatic ring of tranylcypromine [61,65,66,70,
71]; crystallographic analyses reveal that these groups likely protrude
into the methylated lysyl binding pocket, forming favourable hydrogen-
bonding and hydrophobic interactions (Fig. 2) [61,66]. Some of the
tranylcypromine derivatives inhibit cell growth in cancer cell lines includ-
ingmurine acute promyelocytic leukaemia blasts [61,65,72]. In addition, a
number of compounds substituted at the primary amino group display
improved activity relative to tranylcypromine 2 and are selective for the
KDM1 family over related amine oxidases [67–69]. Some of theseFig. 4. Structures of representative iron-chelating inhibitors of the JmjCKDMs. (A) Structures of
2OG oxygenases. Some 2OG oxygenases are inhibited by succinate (33, a co-product of catalysis
be substantially increased in some tumour cells.N-Oxalylglycine (NOG, 32) is a close isostere of
ilies. (B) Structures of hydroxamic acid-containing inhibitors andDaminozide (45). Hydroxamic
and selective 2OG oxygenase inhibitors. Examples include the JmjC KDM inhibitor Methylstat
inhibits JmjC KDMs in vitro. Daminozide (45), a small achiral hydrazide, inhibits the KDM2/7 s
carboxylic acid (2,4-PDCA, 47) is a broad-spectrum 2OG oxygenase inhibitor that chelates acti
of 2,4-PDCA have been prepared via substitution at the 3-position (e.g. 48). Recently, pyridine
inhibit JmjC KDMs via monodentate iron chelation. Other pyridine-containing inhibitors inclu
and the pyridylhydrazone 50, which was recently identiﬁed from a high-throughput screen.
bidentate manner via their pyridyl nitrogen and phenolic oxygen atoms. 5-Carboxy-8-hydr
KDM4E, is a broad-spectrum 2OG oxygenase inhibitor that exhibits moderate selectivity for so
and 7- positions of the 8-hydroxyquinoline ring has resulted in improved selectivity for KDMs (
ylase FIH reveal that IOX1 can induce translocation of the active-site iron (see Figs. 5 and 7). Such
to KDM4A (Fig. 5).compounds are brain-penetrating [67]. Promising preclinical data for
treatment of acute myeloid leukaemia (AML) by targeting KDM1A with
tranylcypromine 2 have provided target validation evidence. A KDM1A
inhibitor has been recently described which, it is reported, shows both
unprecedented in vitro potency (IC50 at 20 nM) and selectivity over all
analysed amine oxidases including KDM1B. This compound (ORY-1001)
is projected to enter clinical trials in 2014 [73].2.2. Substrate mimetics
The preference of the KDM1 subfamily for protein substrates,
as well as their susceptibility to mechanism-based inhibitors (e.g.
tranylcypromine 2), has led to the development of a series of peptides
containing reactive groups selective for KDM1 over MAOs. Peptide frag-
ments of H3 were synthesised with K4 lysine analogues [57,74] and
modiﬁed to contain reactive groups (e.g. cyclopropyl, propargyl)
intended to react with the FAD cofactor of the KDM1 enzymes. A num-
ber of the peptides inhibited KDM1A activity in vitro, with a hydrazine-
derivatised peptide showing the most potent activity (13, Fig. 2C, Ki =
4.4 nM). Mechanistic and crystallographic studies with the propargyl
group-containing peptides (14 and 15, Fig. 2) revealed that inhibition
by these peptides is indeed induced, at least in part, through reaction
with FAD [62,75] (a similarmechanism for inhibition by analogous pep-
tides has also been proposed) [57].tricarboxylic acid (TCA) cycle intermediates and 2OGmimetics. 2OG is a co-substrate of the
), fumarate (34), and 2-hydroxyglutarate (35 and 36). Levels of these small molecules can
2OG. C-α derivatisation of NOG can confer selectivity for different 2OG oxygenase subfam-
acids are establishedmetal chelators andwith appropriate functionalisation can be potent
(44), and SAHA (40), which is a clinically used inhibitor of histone deacetylases that also
ubfamily of JmjC KDMs. (C) Examples of pyridine-based KDM inhibitors. Pyridine-2,4-di-
ve site-bound iron via its pyridyl nitrogen and 2-carboxylate. KDM4-selective derivatives
-containing fragments without a 2-carboxylate group (e.g. 49) have also been reported to
de bipyridyl compounds (e.g. 51 and 52), which chelate iron via both pyridyl nitrogens,
(D) Structures of 8-hydroxyquinoline derivatives. 8-Hydroxyquinolines chelate iron in a
oxyquinoline (IOX1, 54), which was identiﬁed from a high-throughput screen against
me JmjC KDM subfamilies (KDM2/7, KDM3, KDM4, KDM6). Substitution at the 2-, 4-, 5-
e.g. 56-59). Crystallographic studies with KDM4A, KDM6B and the HIF asparaginyl hydrox-
metalmovement is not observed for 4-carboxy-8-hydroxyquinoline (4C8HQ, 55) binding
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Polyamines are knownMAO inhibitors which also inhibit KDM1 [76,
77]. An early screen of bisguanidines and bisbiguanides identiﬁed non-competitive inhibitors of KDM1A with low-micromolar IC50 values (for
representative structures, see Fig. 3) [78]. Two of the compounds were
tested in cell models, resulting in increased expression of tumour sup-
pressor genes as well as ﬂuctuations in levels of H3K4me2 (increase),
KDM4A + NOG
KDM4A + 2,4-PDCA
KDM4A + 52
KDM4A + Daminozide
KDM4A + (R)-2HG KDM4A + (S)-2HG
KDM4A + 4C8HQ KDM4A + IOX1
KDM4A + 38
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Fig. 5. Crystal structures of inhibitors bound to KDM4A. KDM4 inhibitor structures reported to date are for bidentate iron chelators. One chelating group from the inhibitor coordinates
opposite to the iron-binding glutamate residue (Glu190 in KDM4A); however, the second chelating group may coordinate either opposite the ﬁrst iron-binding histidine (His188 in
KDM4A), as observed for 2OG chelation (and for NOG, see top left), or opposite the second histidine (His276 in KDM4A), as observed for 2,4-PDCA (see middle right). The preference
of the two binding modes is likely determined by steric factors. Binding of IOX1 in the active site of KDM4A induces translocation of the active site metal (red arrow, bottom right). In
all structures, the active site iron is substituted for nickel. PDB IDs: 2OQ6 [121], 4AI9 [124], 2WWJ [52], 2YBK [105], 2YBS [105], 2VD7 [104], 3PDQ [134], 4BIS [53] and 3NJY [135].
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marks. Later studies with a series of polyamines (octamines and
decamines) also revealed inhibition of recombinant KDM1A and similar
effects in cells (Fig. 3) [79]. Further derivatives incorporating bisurea
and bisthiourea groups also exhibited KDM1A activity, with two com-
pounds inhibiting growth of non-small cell lung carcinoma cells
(Fig. 3) [80]. Two recent patents also reveal KDM1A inhibition by
amidine- and dithiocarbamate-containing compounds [81,82]. Howev-
er, more detailed mechanistic, selectivity and cell-based studies are re-
quired for the ‘polyamine’ inhibitor class. In particular, it is of interest
to determine to what extent the cell-based observations result from se-
lective KDM1 subfamily inhibition.2.4. Other KDM1 inhibitors
Several types of reversible inhibitors of KDM1have recently been re-
ported. Namolin (26, Fig. 3), a cell-active, reversible inhibitor of KDM1A,
was identiﬁed by screening against the closely related monoamine oxi-
dases MAO-A and MAO-B [49]. Aminothiazoles have been identiﬁed as
weak reversible inhibitors (compounds 27 and 28, IC50 at 249 and
437 μM respectively, Fig. 3) of KDM1A following a fragment-based
screen [83]. The initial hitswere developed to increase potency (29, low-
est IC50 at 7 μM, Fig. 3); however cellular assays using CD86 expression
as amarker for KDM1A inhibition in THP1 cells [84] indicated that these
compounds are not cell-active (EC50 N50 μM).
Fig. 6. Structures of the KDM6 subfamily inhibitor GSK-J1 and derivatives. GSK-J1 (61) is
an iron chelator, which induces metal movement within the active site of KDM6B (for a
view of a crystal structure of GSK-J1 bound in the active site of KDM6B, see Fig. 11). The
ethyl ester prodrug (GSK-J4, 62) is active in cells, whereas the prodrug formof the inactive
analogue GSK-J2 (63) shows no cellular effects (GSK-J5, 64).
Fig. 7. Structures of 2-4(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one (PBIT) and
ebselen. PBIT (65) and ebselen (66) inhibit both the KDM4 and KDM5 subfamilies of
KDMs, probably via removal of the enzyme-bound zinc.
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analyses and biochemical screening, led to the identiﬁcation of an
N′-(1-phenylethylidene)-benzohydrazide series as KDM1A inhibitors.
The optimised compound 30 was found to be highly potent (Ki =
31 nM) and selective over monoamine oxidases (MAO-A and MAO-B
N300 μM), to inhibit cell proliferation of several cancer cell lines, and
to increase H3K4me2 levels in VCaP cells in a dose-dependent manner
[85]. Recently, GSK354, a novel potent (IC50≤ 100 nM), highly selective
(MAO IC50≥ 200 μM) and cell-active inhibitor (31, IC50=1.4 μM, Fig. 3)
of KDM1A has been declared as a chemical probe suitable for use in bi-
ological function studies [86].
3. JmjC KDM inhibitors
3.1. Overview
The 2OG oxygenases were originally identiﬁed as playing roles in
collagen biosynthesis comprising prolyl and lysyl hydroxylations.
Prolyl-4-hydroxylation stabilises the collagen triple helix and conse-
quently, in pioneering inhibition work, collagen prolyl-4-hydroxylases
were targeted for ﬁbrotic diseases [87,88]. These studies led to the iden-
tiﬁcation of various compounds that compete with 2OG and coordinate
to the active site ferrous iron [89]. Prior to the identiﬁcation of the JmjC
KDMs, 2OGoxygenaseswere found to play key roles in the physiological
response to limiting oxygen availability via the post-translational prolyl
and asparaginyl hydroxylation of the hypoxia-inducible transcription
factor (HIF) [90]. Whereas the HIF prolyl hydroxylases (PHD or EGLN
enzymes) are related to the collagen prolyl hydroxylase subfamily of
2OG oxygenases, HIF asparaginyl hydroxylation is catalysed by a JmjC-
type enzyme (factor inhibitingHIF, FIH) but onewhich catalyses a stable
hydroxylation modiﬁcation rather than demethylation via hydroxyl-
ation [90]. Some of the inhibitors developed/applied to the collagen
and HIF hydroxylases, such as N-oxalylglycine (NOG, 32, Fig. 4), have
been found to be useful both as broad-spectrum 2OG oxygenase inhib-
itors, including for the KDMs, and as templates for development by
functionalisation into more speciﬁc inhibitors [89].
There is now a considerable amount of structural information avail-
able for 2OG oxygenases [91,92]. The crystal structures have revealed
substantially conserved Fe(II) and 2OG binding sites; however, differ-
ences in Fe(II) and 2OG binding sites are subfamily-characteristic and
can be exploited for the development of selective inhibitors [92,93]. As
may be anticipated from the diversity of substrate types for 2OG
oxygenases – proteins, nucleic acids, small molecules and lipids –
there are greater variations in the substrate binding elements, which
separately, or in conjunction with Fe(II) binding, can be exploited for
the development of selective inhibitors. However, approaches involving
solely mimicking the binding of histone substrates to the JmjC KDMs
raise the possibility of selectivity issues relating to non-2OG oxygenase
proteins that bind the same/similar histone sequences. Further, it is im-
portant to note that 2OG oxygenase catalysis involves an ordered se-
quential mechanism involving conformational changes that are not
yet fully deﬁned and probably not (completely) accessible by crystallo-
graphic studies. For example, recent studies with inhibitors have dem-
onstrated that some compounds can induce movement (N1.0 Å) of the
metalwithin the active site [53,94]. Thus, structural analyses by solution
phase techniques (e.g. NMR) are of importance in the ﬁeld [95,96].
It is alsoworthmentioning that inhibition of 2OG oxygenases by en-
dogenous smallmolecules is of pathophysiological relevance.Mutations
to tricarboxylic acid (TCA) cycle enzymes are common in tumours and
can result in very substantial increases in the concentrations of succi-
nate (33, Fig. 4), fumarate (34, Fig. 4), or 2-hydroxyglutarate ((S/R)-
2HG, 35 and 36, Figs. 4/5) [97–99]. The formation of 2HG is of particular
biochemical interest — ‘gain of function’ mutations cause isocitrate de-
hydrogenase (IDH) 1 and 2 to convert 2OG into 2HG, as well as produce
2OG from isocitrate [100]. The increases in TCA intermediate/2HG levels
are proposed to be pro-oncogenic, at least in part due to inhibition of2OG oxygenases involved in transcriptional regulation. Succinate [101,
102], which is a co-product of 2OG oxygenase catalysis, fumarate [103,
104], and 2HG all inhibit 2OG oxygenases, though rather weakly (in
the μM to mM range for KDM2A, KDM4A, KDM4C and KDM5B, as
shown with isolated proteins and in cells [105,106]), via competition
with 2OG [103,107], though more complex mechanisms are possible.
It is also notable that succinate release is rate-limiting for some 2OG
oxygenases [108] and that high levels of the cosubstrate 2OG can be in-
hibitory [109]. Further, in assessing the potential relevance of 2OG oxy-
genase inhibition by endogenous 2OG competitors, consideration
should be given to the 2OG/inhibitor concentrations in cells, enzyme
concentration, and 2OG KM/KD values; the latter can vary substantially
(N100-fold) [110]. Ester derivatives of TCA intermediates, 2HG and
2OG have been used as prodrugs in cellular functional studies because
the parent di-acids have poor cell penetration [111].
In the following sections we describe studies on various types of
JmjC KDM inhibitors— our objective is not to be comprehensive (espe-
cially with respect to the patent literature) but to illustrate different
types of inhibitors developed to date and make general points.
Reﬂecting current reports, our focus is on active site-directed inhibitors,
but (evidently) there is also potential for the inhibition of auxiliary do-
mains, and by targeting the non-active site regions in the core JmjC do-
main. The latter approach is exempliﬁed by compounds that act on the
zinc-binding domain of KDM4 [112]. It is also notable that recent work
has focused on inhibition of the JmjC KDMs, with fewer reports to date
on the nucleic acid oxygenases such as FTO and the TET enzymes
[113–115].
3.2. N-Oxalyl amino acid-based JmjC KDM inhibitors
N-Oxalylglycine (NOG, 32, Fig. 4) is a closely related analogue of 2OG
wherein the C-3 methylene group is replaced with an NH group to give
an N-oxalyl amide derivative that likely stalls the catalytic reaction by
hindering oxygen binding to the active site iron. Although ﬁrst de-
scribed as a prolyl hydroxylase (PHD) inhibitor, NOG is a broad-
spectrum inhibitor ofmany2OG oxygenases [116], which, following ini-
tial work with KDM4E [104], has been shown to inhibit all tested JmjC
KDMs [53]. Multiple crystal structures for 2OG oxygenases complexed
with NOG have been reported (e.g. for KDM4A, KDM6A, PHF8; see
Figs. 5 and 11); the structures reveal that NOG binds to the active site
Fig. 8. Structures of histone substrate-competitive JmjC KDM inhibitors. Compounds 67-69 comprise both iron-chelating groups and histone fragments to enable potency and selectivity
for JmjC KDMs. The lysinemethyltransferase inhibitor BIX-01294 (70) also inhibits JmjC KDMs; development of BIX-01294 analogues has resulted in JmjC KDM-speciﬁc inhibitors (71 and
72). Crystallographic studies of 71with KDM7A suggest that the compound may compete with the histone substrate for binding (Fig. 11).
Baicalein, 74
Epigallocatechin gallate, 75 
Caffeic acid, 78 
Dopamine, 76
Myricetin, 73
Haematoxylin, 77 Tripartin, 79 Pyrido[1,2-a]indoles
Fig. 9. Structures of ﬂavonoid, catechol, tripartin, and pyrido[1,2-a]indole inhibitors of JmjC KDMs. Numerous ﬂavonoid and catechol compounds have been identiﬁed as JmjC KDM inhib-
itors from high-throughput screening, includingmyricetin (73) and dopamine (76). Precisemode(s) of inhibition, however, are unclear. Tripartin (79) is an indanone-based natural prod-
uct that was shown to inhibit KDM4. Pyrido[1,2-a]indoles have been recently reported to inhibit KDM4C via unknown mechanism(s).
Fig. 10. View from a crystal structure of KDM4A with bound peptide substrate analogue (sequence ARK(me3)SCGGK, yellow) and N-oxalyl-D-cysteine (DNOC, pink). The peptide and
DNOC form a disulﬁde linkage within the active site (dashed line, circled). Replacing the disulﬁde bond with a sulﬁde led to the development of a stable analogue exhibiting potent
and selective inhibition for the KDM4 subfamily (68, Fig. 8). PDB ID: 3U4S [141].
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Fig. 11.Views fromcrystal structures of inhibitors bound to theKDM6andKDM2/7 subfamilies. As observed in inhibitor structureswith KDM4A, bidentate iron chelatorsmay adopt one of
two coordination modes around the iron, with one iron-binding group positioned opposite to the iron-binding carboxylate residue (Glu1148 in KDM6A, Glu1389 in KDM6B, Asp249 in
PHF8 and Asp284 in KDM7A) and the other opposite to one of the iron-binding histidines. Both IOX1 (54, Fig. 4) and GSK-J1 (61, Fig. 7) induce metal translocation in KDM6B (note:
the crystal structure of GSK-J1 binding was solved using mouse KDM6B). E67 (71, an analogue of the lysine methyltransferase inhibitor BIX-01294, 70, Fig. 8) binds away from the iron
binding site in KDM7A, suggesting no metal chelation. PDB IDs: KDM6A + NOG, 3AVS (metal = nickel) [157]; KDM6B + IOX1, 2XXZ (metal = nickel) [53]; mKDM6B + GSK-J1,
4ASK (metal = cobalt) [94]; PHF8 + NOG, 3KV4 (metal = iron) [158]; PHF8 + Daminozide, 4DO0 (metal = zinc) [124]; KDM7A+ E67, 3U78 (metal = nickel) [142].
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groups, with its glycine carboxylate occupying the same position as
the C-5 carboxylate of 2OG. Although NOG is a relatively broad-
spectrum inhibitor, it should be noted that the potency of 2OG oxygen-
ase inhibition by NOG does vary substantially [53]. The cell-penetrating
dimethyl ester form of NOG, dimethyl N-oxalylglycine (DMOG), has
foundwidespread applications as a hypoxia mimetic [117,118] because
it inhibits both HIF prolyl and asparaginyl hydroxylases resulting in
upregulation and activation respectively of the HIF system [119]. It is
possible that some of the observed cellular effects of DMOG result
from JmjC KDM, or other 2OG oxygenase, inhibition [53].
The potential for selective inhibition of the JmjC subfamilywas dem-
onstrated by pioneering studies on inhibition of the HIF hydroxylases.
Comparison of PHD2 and FIH crystal structures led to the proposal
that C-alpha derivatisation of NOG may lead to FIH-selective inhibitors
[120]. Indeed the NOG derivative N-oxalyl-D-phenylalanine (37, Fig. 4)
is selective for FIH over the PHDs; the dimethyl ester prodrug form is
an active FIH inhibitor in cells [119]. The benzyl group of 37 occupies a
hydrophobic binding pocket in FIH close to the Fe(II) binding site
which is absent in the PHDs.
As with FIH, the KDM4 subfamily also possess a hydrophobic pocket
close to the Fe(II) centre, whichmay be exploited for selective inhibition
[121]. A combined approach involving structure-guided design coupled
with disulﬁde-based dynamic combinatorial chemistry employing non-denaturingmass spectrometry (DC-MS) for screeningwas employed to
identify disulﬁdes that occupied this pocket, which is larger in the
KDM4s compared to FIH. Subsequently, stable analogues of disulﬁdes
that were observed to bind relatively tightly by MS were prepared. It
was found that substitution at the para position of the phenyl ring of
N-oxalyl-D-tyrosine resulted in molecules that inhibit KDM4E in the
micromolar range and which are selective over both FIH and the PHDs
[52]. A crystal structure of KDM4A in complex with one of the potent
inhibitors (38) was obtained (Fig. 5).
Analysis of the X-ray crystal structure of KDM4A in complex with
NOG (occupying the 2OG binding site) and a trimethylated peptide
(occupying the substrate pocket, PDB ID: 2OQ6) [121] led to the design
and synthesis of NOG derivatives substituted with an alkyl-linked
dimethylaniline group in order to mimic the interactions of the
trimethylated peptide with the protein (Fig. 4) [122]. These derivatives
maintain the inhibitory action of NOG against KDM4A, and exemplify
the strategy of linking the 2OG and peptide substrate binding sites for
JmjC KDM inhibition (for representative structures, see 39, Fig. 4) [122].
3.3. Hydroxamic acid-based JmjC KDM inhibitors
In early screenings for templates that inhibit the JmjC KDMs,
work with KDM4E identiﬁed hydroxamic acid inhibitors, including
conformationally constrained 2OG analogues. Interestingly, amongst
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deacetylase (HDAC) inhibitor SAHA (Vorinostat, 40, Fig. 4) [104]. This
observation raises the possibility that some of the pharmacological ef-
fects of SAHA may result from inhibition of targets other than HDACs,
including the JmjC KDMs.
The inhibitory activity of SAHA and the knowledge that hydroxamic
acids are good metal chelators led to the design of inhibitors where the
2-oxoacid group of 2OG is replacedwith a hydroxamic acidmoiety [123,
124]. The resulting compounds containing the hydroxamic acid scaffold
show good selectivity for the KDM4 family over the related HIF PHDs.
Molecules where the hydroxamic acid scaffold is connected through
an alkyl linker to a dimethylamino group were designed based on the
KDM4A:NOG crystal structure (PDB ID: 2OQ6 [121]) [125]. The protein
interaction of the protonated tertiary amine likely mimics those of the
positively charged Nε-methylated lysine residue. A linker of eight car-
bon atoms was found to give optimum potency for KDM4A and
KDM4C inhibition (42, Fig. 4). Replacing the dimethylamino group of
42 with a cyclopropane ring (43, Fig. 4) shifted the selectivity from
the KDM4 subfamily to the KDM2/7 subfamily. It is proposed that the
cyclopropane group occupies a hydrophobic pocket present in the
KDM2/KDM7 subfamily.
The strategy of designing inhibitors capable of binding to both the
2OG and substrate binding pockets was applied in the discovery of
Methylstat (44, Fig. 4), which contains a carboxyhydroxamic acid
designed to occupy the 2OG binding pocket attached to a protonated ly-
sine mimic through a hydrocarbon linker. Whilst the free acid inhibits
KDM4C in the micromolar range, the methyl ester was found to be
necessary for cell activity [126].
3.4. Daminozide
Daminozide (45, Fig. 4) is a (now largely discontinued) agrochemical,
which inhibits 2OG oxygenases involved in gibberellin biosynthesis in
plants [127]. Following screening of a set of potential 2OG analogues,
Daminozide was found to also inhibit the KDM2/7 family enzymes
(KDM2A (IC50 = 1.5 μM) and PHF8 (IC50 = 0.55 μM)) — somewhatK206
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Y132 Y132 Y
KDM4A + 2,4-PDCA KDM4A + IOX1
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Fig. 12. Analysis of heterocyclic iron chelators binding to JmjC KDMs. Overlays of reported stru
aromatic groups within the active sites. In structures of KDM4A with bound 2,4-PDCA (sectio
an aromatic group is positioned between themetal site and the 2OGC-5 carboxylate binding site
of this aromatic group is likely stabilised by π-π stacking interactions with Phe185. For bicyclic
discrete orientations (ring positions B or C, sections E and F). Despite IOX1 inducing translocatio
by 4C8HQ, suggesting metal movement may be preferred to altered ring-positioning, at least iunexpectedly given its small size. Some analogues of Daminozide, includ-
ing a hydroxamic acid variant (46, Fig. 4), also revealed inhibition, albeit
with poorer selectivity (and in some cases, poor compound stability).
Daminozide is selective for the KDM2/7 subfamily over other members
of the human JmjC KDMs. Crystallographic studies reveal Daminozide
chelates the active site iron via its dimethylamino nitrogen lone pair
and C-4 carbonyl group, with its C-1 carbonyl occupying the same site
as the 2OG C-5 carboxylate (Figs. 5/11). This selectivity may be engen-
dered by the more lipophilic region created by the Tyr257, Val255 and
Ile191 residues adjacent to Fe(II) in the KDM2/7 subfamily compared to
the more hydrophobic residues in the corresponding regions in other
JmjC demethylases, as indicated by crystallographic studies [124].
3.5. Pyridine dicarboxylates and related JmjC KDM inhibitors
Pyridine dicarboxylates aremore rigid 2OG analogues thanNOG and
the acyclic hydroxamic acids. Of the various pyridine-dicarboxylate
regioisomers, pyridine-2,4-dicarboxylic acid (2,4-PDCA, 47, Figs. 4/5/
12) is the broadest-spectrum 2OG oxygenase inhibitor, and is an inhib-
itor of most JmjC KDMs. [104] It is used as dimethyl or diethylester
prodrugs for cellular studies where it has been shown to inhibit JmjC
KDM activity by antibody- and MS-based assays [128].
The observation that the 2OG binding pocket is smaller in the HIF
prolyl hydroxylases than the KDM4 demethylase subfamily led to the
design of 2,4-PDCA derivatives substituted at the C-3 position to block
binding in PHD2 whilst retaining potency against KDM4E. Notably,
one of the most potent inhibitors was the 3-amino derivative 48
(Fig. 4) [129]. Although the 2-carboxy group in 2,4-PDCA and its deriv-
atives is involved in binding to Fe(II) in the active site, 3-amino-4-
carboxy pyridines lacking the 2-carboxy group (e.g. 49, Fig. 4) have
also been recently described as JmjC inhibitors [130]. The 4-carboxy
group, which mimics the 2OG carboxylate, is also not essential for
JmjC inhibition; screening of the National Cancer Institute's ‘Diversity
Set’ library resulted in the identiﬁcation of a pyridylhydrazone deriva-
tive as a micromolar to sub-micromolar inhibitor of KDM4A–E,
KDM6B and KDM5A (50, Fig. 4) [131]. This compound (JIB-04) wasK206
Y132
E190
132 Y132
KDM4A + 4C8HQ
KDM4A + 52
Overlay of Structures
D
ctures of heterocyclic inhibitors bound to JmjC KDMs reveal preferential positioning of 2
n A), IOX1 (section B), 4C8HQ (section C) and the bipyridine compound 52 (section D),
deﬁned by residues Tyr132 and Lys206 (ring position A, section E). In KDM4A, theposition
chelators (IOX1, 4C8HQ and 52), the other aromatic groups are positioned in one of two
n of the active sitemetal, the position of quinolyl bicyclic system is identical to that adopted
n KDM4A.
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inhibit tumour growth in mice. The Z-isomer was less efﬁcacious in
causing cell death, possibly because of reduced demethylase activity as a
result of being unable to chelate Fe(II) in the active site in a bidentate
manner.3.6. Bipyridine and related JmjC KDM inhibitors
2,2′-Bipyridine and its derivatives are precedented 2OG oxygenase
inhibitors including of the HIF PHDs [132,133]. Screening efforts
have shown that the carboxy derivative 4′-(methoxycarbonyl)-2,2′-
bipyridine-4-carboxylic acid (51, Fig. 4) inhibits KDM4E in the micro-
molar range [104]. More potent analogueswere discovered by replacing
themethyl esterwith a range of substituted amides. Optimisation of the
amide substituent led to compound 52 (Fig. 4) which has 40-fold im-
proved KDM4E activity (180 nM) compared to 51 [134]. Crystallograph-
ic studies demonstrated that 52 binds to KDM4A in the active site,
chelating Fe(II) through the two pyridyl nitrogens (Figs. 5/12).3.7. 8-Hydroxyquinoline-based JmjC KDM inhibitors
A high-throughput screen led to the identiﬁcation of a variety of 4-,
5-, and 7-substituted 8-hydroxyquinolines that are active against
KDM4E [135]. The 5-substituted hit compounds were most active and
were validated in a secondary assay against KDM4A and KDM4E.
These compounds also showed activity against FIH and PHD2 although
with somewhat weaker potency. The most potent compound,
5-carboxy-8-hydroxyquinoline (IOX1, 54, Fig. 4) displayed an IC50 of
0.2 μM in vitro and was active in cells with an EC50 of 87 μM. IOX1 is a
broad-spectrum 2OG oxygenase inhibitor, displaying sub-micromolar
in vitro potency against KDM4A/C/D/E and KDM3A, micromolar IC50s
against KDM6A, KDM2A, PHF8 and KDM5C, and high-micromolar activ-
ity against BBOX1 [53]. IOX1 chelates Fe(II) in the enzymeactive site in a
bidentate manner via its quinoline nitrogen and phenol oxygen atoms.
The carboxylic acid at the 5-position interacts with Tyr132 and Lys206
in a way similar to the acyclic 2OG mimetic NOG (Figs. 5/11/12).
The regioisomer of IOX1, 4-carboxy-8-hydroxyquinoline (4C8HQ, 55,
Fig. 4) binds in an analogous way to IOX1 by chelating Fe(II) and
interacting with Tyr132 and Lys206 (Figs. 5/12). However, in the case
of IOX1 54, the position of the active-site metal is shifted relative to its
position in the absence of inhibitor (as observed for a selective KDM6
inhibitor, see below) [53]. This iron translocation may be related to
the difference in potency between IOX1 54 and 4C8HQ 55.
The activity of the 8HQ-based KDM4 inhibitor 59 (Fig. 4) has been
reported to be related to suppression of initiation of infection by herpes
simplex virus, suppression of propagation of infection to adjacent cells
and suppression of reaction in latently infected sensory neurons via
inhibition of the initiation stage [136]. These results suggest that
chromatin remodelling via small-molecule modulation may be a viable
strategy for antiviral therapy at an early stage of infection. More
generally they suggest potential of ‘epigenetic’ therapies for treatment
of infectious diseases.
Photoafﬁnity probes show promising utility for identiﬁcation and
quantiﬁcation of proteins and mapping molecular interactions in cells
[137]. Such a photoafﬁnity probe (60, Fig. 4) for 2OG oxygenaseswas de-
veloped by coupling IOX1 to a photoactivatable crosslinking group and
biotin as an afﬁnity-puriﬁcation tag [138]. The resulting probe allowed
the identiﬁcation of KDM2A in HEK293T cells via photo-crosslinking
and afﬁnity puriﬁcation coupled to MS analysis. In an effort to develop
this methodology for proﬁling various 2OG oxygenases from different
cell types, the Ugi four-component reaction was exploited to enable em-
pirically guided optimisation of probes for speciﬁc tasks by enabling the
modular assembly of probe scaffolds with a diverse set of photoreactive
groups, detection handles and inhibitor attachment points [139].3.8. A small-molecule probe for KDM6
The ﬁrst small-molecule selective probe for the KDM6 subfamily
(KDM6A and KDM6B) is GSK-J1 (61, Fig. 6), with its corresponding
cell-active ethyl ester prodrug GSK-J4 (62, Fig. 6) [94]. This active site-
binding inhibitor reduced the KDM6A- and KDM6B-mediated
lipopolysaccharide-induced proinﬂammatory cytokine production by
human primary macrophages. GSK-J1 chelates the active site Fe(II)
and contains a propanoic acid side-chain that mimics 2OG side chain
binding: like IOX1 (see above), GSK-J1 induces movement of the active
site metal (Fig. 11). The negative control compound GSK-J2 (63, Fig. 6),
is a regioisomer of the pyridine moiety of GSK-J1 which cannot engage
in bidentate metal chelation and renders the molecule inactive (for
the corresponding prodrug GSK-J5, see 64, Fig. 6). However, GSK-J4
has also been reported to inhibit the KDM5 subfamily in vitro (~20-
fold less active relative to KDM6 inhibition) further highlighting the dif-
ﬁculties in achieving selectivity for this class of enzymes.
The benzisothiazol-3-one ring system is currently being pursued for
KDM5 inhibitor discovery. 2-4(4-Methylphenyl)-1,2-benzisothiazol-
3(2H)-one (PBIT, 65, Fig. 7) was recently identiﬁed as an inhibitor of
KDM5B (IC50 = 3 μM) through a high-throughput screen programme.
Its analogue, Ebselen (66, Fig. 7), also exhibits similar inhibitory activity.
PBIT inhibits KDM5A/B/C but does not inhibit KDM6A/B. While
benzisothiazol-3-ones have also been shown to inhibit the KDM4 sub-
family [112,135], it is possible that selectivitymay be achievedwith fur-
ther medicinal chemistry efforts. PBIT is cell-active and can inhibit
transiently overexpressed KDM5B, thereby increasing global levels of
H3K4me3. Although the mechanism of action of these compounds is
unknown, it is possible that ejection of enzyme-bound zinc may be im-
portant for their activity (as observed for inhibition of KDM4A by
Ebselen) [112].
3.9. JmjC KDM inhibitors targeting the substrate binding pocket
The JmjC KDMs have very distinct, sometimes overlapping, histone
H3 substrate preferences. Emerging work is focusing on the use of his-
tone peptide substrate mimetics as a strategy to achieve inhibitor selec-
tivity for speciﬁc (sets of) JmjC KDMs. In one study, a systematic
truncation analysis of histone H3K9me3/2 peptides and PHF8/KDM4A/
C turnover demonstrated differential activities amongst the JmjC
KDMs for the sameH3 sequence [140]. The peptideswere then convert-
ed to inhibitors by conjugating a promiscuous iron chelatormotif, uracil,
onto the K9 position of the truncated peptides, and the degree of pep-
tide length imparted selectivity for JmjC KDMs recognising the same
H3K9 methylation (for representative structure, see 67, Fig. 8).
In another study, N-oxalyl-D-cysteine (DNOC) and a set of histone
H3 peptides systematically substituted with cysteine residues were
screened by techniques including non-denaturing mass spectrometry
for binding to KDM4A and other KDM4 subfamily enzymes. Following
identiﬁcation of mixed disulﬁdes that bound (for a view of a crystal
structure on one cross-linked peptide–DNOC conjugate in the active
site of KDM4A, see Fig. 10), stable analogues were synthesised (via rad-
ical ene reaction) resulting in an inhibitor selective for the KDM4 sub-
family over KDM3A, KDM6B and KDM2A (68, Fig. 8) [141]. Moreover,
by cross-linking to an H3K36 sequence (which binds to KDM4A–C but
not D/E, 69, Fig. 8), it was possible to demonstrate intra-subfamily selec-
tivity (i.e. selectivity for KDM4A–C over KDM4D/E). Overall, these re-
sults provide proof of principle that selective inhibition of not only
JmjC subfamilies, but also isoform subgroups, is achievable by utilising
binding to both 2OG and substrate binding sites.
The development of small molecules that mimic histone substrate
binding for the JmjC KDMs is at an early stage. The G9a and G9a-like
H3K9 methyltransferase inhibitors BIX-01294 (70, Fig. 8) and E67 (71,
Fig. 8) were shown to inhibit the H3K9me2 and H3K27me2
demethylase KDM7A with IC50 values in the low-micromolar range
[142]. The E67-2 analogue (72, Fig. 8) retained potency against
1428 C.C. Thinnes et al. / Biochimica et Biophysica Acta 1839 (2014) 1416–1432KDM7A with N30-fold selectivity over G9a-like methyltransferases. All
three compounds demonstrated selectivity for KDM7A over KDM5C.
Both E67 and E67-2 displayed reduced cytotoxicity in mouse and
human primary ﬁbroblasts compared with BIX-01294. It is proposed
that these compounds act as H3 substrate analogues as supported by
crystallographic analyses of E67 complexed with KDM7A (Fig. 11).
These studies imply further work on substrate-competing inhibitors of
the JmjC KDMs will be worthwhile.
3.10. Inhibition by ﬂavonoids, catechols and other compounds
Flavonoids and catechols are natural products that have been dem-
onstrated to inhibit a number of 2OG oxygenases, including the JmjC
KDMs (and many other enzymes) [109,143–145]. A high-throughput
screen of the LOPAC bioactive library against KDM4E identiﬁed many
ﬂavonoids (e.g. myricetin 73, baicalein 74 and epigallocatechin gallate
75, Fig. 9) and catechols (e.g. dopamine 76 and its derivatives, and
haematoxylin 77, Fig. 9) as low-micromolar inhibitors [146]. In another
study, a catechol series (caffeic acid (78, Fig. 9) and derivatives) from a
diversity-optimised natural product librarywas found to inhibit KDM4C
and KDM6A but not PHF8 [147]. Caffeic acid 78was a hit from a KDM6B
HTS [148]. While the metal-chelating properties of ﬂavonoids and
catechols is, in part, thought to contribute to KDM inhibition, direct
competition with 2OG is not observed, and it is possible that multiple
factors contribute to their inhibitory effect. Although these compounds
are unlikely to be useful from a pharmaceutical perspective, these
results do raise the possibility that natural products obtained from the
diet may affect chromatin modiﬁcation status.
Recently, the natural product Tripartin (79, Fig. 9), which is a
dichlorinated indanone isolated from the culture broth of the Strepto-
myces sp. associated with a larva of a dung beetle, has been reported
as a JmjC KDM inhibitor; cell-based evidence for KDM4 inhibition was
presented, though selectivity studies on isolated enzymes have not yet
been reported [149].
The majority of JmjC KDM inhibitors identiﬁed to date incorporate
carboxylic acids/carboxylic acid analogues, leading to use of pro-drug
ester forms for sufﬁcient cellular activity. Interestingly, a series of
pyrido[1,2-a]indoles are reported to inhibit KDM4C in the sub-
micromolar range as the acid, ester, and primary amide forms; the
mode of action of these compounds is not yet established (Fig. 9)
[150,151].
4. ‘Pan’ KDM1 and JmjC KDM inhibitors
‘Pan’-histone demethylase inhibitors 80 and 81 (Fig. 13) targeting
both KDM1 and JmjC KDMs were synthesised in an effort to address
the observation that both KDM1 and KDM4 are coexpressed and
colocalisewith the androgen receptor in prostate cancer [152]. These in-
hibitors were created by covalently linking the known KDM1 inhibitor
tranylcypromine (2, Fig. 2) with the JmjC KDM inhibitor templates
4-carboxy-2,2′-bipyridine (51, Fig. 4), or IOX1 (54, Fig. 4) [153]. Both
80 and 81 increased H3K4 and H3K9 methylation levels in cells and
led to growth arrest and apoptosis in LNCaP prostate and HCT1168180
Fig. 13. Structures of 'pan-KDM' inhibitors. Compounds 80 and 81 (as racemates) combine
KDM1 inhibitor tranylcypromine 2 with the JmjC KDM inhibitors 4-carboxy-4′-
carboxymethoxy-2,2′-bipyridine 51 and IOX1 54 respectively. These dual inhibitors in-
duce cell growth inhibition and apoptosis in prostate and colon cancer cell lines, but not
in noncancer mesenchymal progenitor cells.colon cancer cell lines; this activity was not observed with single 2, 51
or 54, or a combination of 2 and 51. Further, the inhibitors were
observed to cause little or no apoptosis in non-cancerous mesenchymal
progenitor (MePR) cells. Thus, although there is undoubtedly consider-
able scope for optimisation, inhibitors targeting sets of both KDM1 and
JmjC KDMs, may have potential for cancer-selective applications.5. Future directions
In this reviewwe hope to have summarised the pioneering progress
on the inhibition of the human KDMs and given some sense of the ex-
citement in the ﬁeld from both basic science and therapeutic perspec-
tives. Over the past decade or so our perceptions of the roles and
extent of protein and nucleic acid methylation have changed consider-
ably. Amajor change has comewith the realisation that themethylation
of protein, DNA and RNA molecules can be directly and frequently re-
versed by methyl group oxidation catalysed by enzymes from the
amine oxidase and 2OG oxygenase superfamilies. A third mechanism
of direct demethylation, i.e. by thiolate-mediated nucleophilic displace-
ment, is involved in nucleic acid repair in both prokaryotes and eukary-
otes, but has not been shown to be involved in transcriptional
regulation [154].
Inhibition of histone demethylases and methyltransferases has sub-
stantial potential for the regulation of gene expression by treatment
with small molecules. As outlined in the preceding sections, studies on
the selective inhibition of the catalytic domain of both the human
KDM1/LSD and the JmjC families of KDMs are progressing rapidly. Al-
though these studies are at a relatively early stage, the signs are that
with sufﬁcient medicinal chemistry efforts, it will be possible to make
highly potent and selective inhibitors of the catalytic domains of both
families of human KDMs. To date most KDM1 and JmjC KDM inhibition
efforts have been focused on the extension of known types of inhibitors
for other familymembers to the KDMs, i.e. mechanism-based inhibition
of the KDM1s and active site iron chelators for the JmjC KDMs. It is likely
that the extension of those methods, including by competing with his-
tone substrate binding interactions, will lead to highly selective inhibi-
tors of the catalytic domains. As time progresses it is likely that new
types of inhibitors will emerge — such as those involving substrate
competition and allosteric interactions. Additionally, although more
challenging, the identiﬁcation of small molecules that promote KDM
activity is of potential therapeutic interest and this might be the focus
of some future academic efforts.
There is already strong evidence that the biological roles of the
KDMs cannot be simply explained as ‘erasure’ of methylation. All
human KDMs are predicted to contain non-catalytic ‘binding’ domains,
and their interaction with nucleosomes/chromatin perhaps might be
best viewed as protein–protein/nucleic acid interactions in which the
covalent methylation/demethylation processes are a component. Per-
turbation of the interaction of theKDMbinding domains offers potential
for therapeutic manipulation. However, such an approach requires the
issue of how best to assay KDM activity in cells.
To date, cell-based assays have mostly focused on antibody-based
methods for measuring methylation status, sometimes coupled to
‘reporter gene’ assays, though not always under physiologically relevant
conditions. Data relating to the methylation status associated with par-
ticular DNA sequences can also be acquired via chromatin immunopre-
cipitation studies. As with studies on other chromatin-modifying
enzymes, in few cases are the effects of KDM inhibition directly connect-
ed with clear phenotypes at the physiological level. Mutations to the
genes encoding for someKDMs are linked to pathophysiological pheno-
types— and one interesting avenuewill be to attempt to replicate these
phenotypes using selective small-molecule inhibitors. Accumulating
evidence, however, indicates that multiple post-translational modiﬁca-
tions contribute to the emergence of phenotypes including pathophys-
iological ones.
1429C.C. Thinnes et al. / Biochimica et Biophysica Acta 1839 (2014) 1416–1432Thus, small-molecule ‘epigenetic therapies’may be required to inhib-
it multiple targets – at least for optimal therapeutic beneﬁt – perhaps
aimed atmodulating sets of post-oligomerisationmodiﬁcations associat-
edwith speciﬁc regions of chromatin. Achieving this in a rationalmanner
will require substantially more knowledge of the chemical details of ge-
netic processes than we presently possess and acquiring such detailed
knowledge is likely to take some time— in themeantime it will be inter-
esting to study the effects of combinations of inhibitors targeting differ-
ent regulatory components of the (epi)genetic machinery.
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